BCRB 2018

19/09/2018

Boosting in situ vaccination effect of RT

Herrera FG et al CA Cancer J Clin 2017

• Pharmacological activation of APCs  because immunomodulatory effects of RT are often not sufficient to trigger effective antitumor immune response due to potent immune suppression in tumor micro-environment and draining lymph node • E.g. agonists of stimulator receptor CD40 and to TLR

T-cell priming

Herrera FG et al CA Cancer J Clin 2017

• Agonistic antibodies directed against costimulatory molecules on T- cells and/or blocking antibodies against coinhibitory molecules to increase T-cell function • E.g. CTLA-4 blockade (ipilimumab)

Ribas, NEJM 2015

23